Currently, the EGFR monoclonal antibody cetuximab is the only target drug that has been approved by the US FDA in the treatment for HNSCC [32].CDKN2A, a tumor-suppressor gene which encodes the cell cycle regulator p16INK4a, has been extensively investigated to be associated with HNSCC. Here, CDKN2A is linked to head and neck squamous cell carcinoma.